Tang Bufu

Mr. Tang Bufu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2020 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
TBTang Bufu
Tang Bufu
JZJinyu Zhu
Jinyu Zhu
JLJie Li
Jie Li
KFKai Fan
Kai Fan
YGYang Gao
Yang Gao
JJJiansong Ji
Jiansong Ji
Background: In this study, we comprehensively analyzed genes related to ferroptosis and iron metabolism to construct diagnostic and prognostic models and explore the relationship with the immune microenvironment in HCC.Methods: Integrated analysis, cox regression and the least absolute shrinkage and selection operator (LASSO) method of 104 ferroptosis- and iron metabolism-related genes and HCC-related RNA sequencing were performed to identify HCC-related ferroptosis and iron metabolism genes.Results: Four genes (ABCB6, FLVCR1, SLC48A1 and SLC7A11) were identified to construct prognostic and diagnostic models. Poorer overall survival (OS) was exhibited in the high-risk group than that in the low-risk group in both the training cohort (P < 0.001, HR = 0.27) and test cohort (P < 0.001, HR = 0.27). The diagnostic models successfully distinguished HCC from normal samples and proliferative nodule samples. Compared with low-risk groups, high-risk groups had higher TMB; higher fractions of macrophages, follicular helper T cells, memory B cells, and neutrophils; and exhibited higher expression of CD83, B7H3, OX40 and CD134L. As an inducer of ferroptosis, erastin inhibited HCC cell proliferation and progression, and it was showed to affect Th17 cell differentiation and IL-17 signaling pathway through bioinformatics analysis, indicating it a potential agent of cancer immunotherapy.Conclusions: The prognostic and diagnostic models based on the four genes indicated superior diagnostic and predictive performance, indicating new possibilities for individualized treatment of HCC patients.Graphical

26 September 2023 in International Journal of Surgery
Verified
Journal Article
Open access
HFHongjie Fan
Hongjie Fan
XXXuancheng Xie
Xuancheng Xie
ZPZhenzhu Pang
Zhenzhu Pang
LZLicai Zhang
Licai Zhang
DRDing Rong
Ding Rong
CZChuansheng Zheng
Chuansheng Zheng
Purpose: To evaluate the risk of pneumothorax in the percutaneous image-guided thermal ablation (IGTA) treatment of colorectal lung metastases (CRLM). Methods: Data regarding patients with CRLM treated with IGTA from five medical institutions in China from 2016 to 2023 were reviewed retrospectively. Pneumothorax and non-pneumothorax were compared using the Student’s t-test, χ2 test and Fisher’s exact test. Univariate logistic regression analysis was conducted to identify potential risk factors, followed by multivariate logistic regression analysis to evaluate the predictors of pneumothorax. Interactions between variables were examined and used for model construction. Receiver operating characteristic curves and nomograms were generated to assess the performance of the model. Results: A total of 254 patients with 376 CRLM underwent 299 ablation sessions. The incidence of pneumothorax was 45.5%. The adjusted multivariate logistic regression model, incorporating interaction terms, revealed that tumour number [odds ratio (OR)=8.34 (95% CI: 1.37–50.64)], puncture depth [OR=0.53 (95% CI: 0.31–0.91)], pre-procedure radiotherapy [OR=3.66 (95% CI: 1.17–11.40)], peribronchial tumour [OR=2.32 (95% CI: 1.04–5.15)], and emphysema [OR=56.83 (95% CI: 8.42–383.57)] were significant predictive factors of pneumothorax (all P<0.05). The generated nomogram model demonstrated a significant prediction performance, with an area under the receiver operating characteristic curve of 0.800 (95% CI: 0.751–0.850). Conclusions: Pre-procedure radiotherapy, tumour number, peribronchial tumour, and emphysema were identified as risk factors for pneumothorax in the treatment of CRLM using percutaneous IGTA. Puncture depth was found to be a protective factor against pneumothorax.

12 August 2020 in Research Square
Verified
Preprint
Open access
PDF file
BZBaohui Zhang
Baohui Zhang
TBTang Bufu
Tang Bufu
JGJianyao Gao
Jianyao Gao
JLJiatong Li
Jiatong Li
LKlingming kong
lingming kong
LQLing Qin
Ling Qin
BackgroundHypoxia plays an indispensable role in the development of hepatocellular carcinoma (HCC). However, there are few studies on the application of hypoxia molecules in the prognosis predicting of HCC. We aim to identify the hypoxia-related genes in HCC and construct reliable models for diagnosis, prognosis and recurrence of HCC patients as well as exploring the potential mechanism.MethodsDifferentially expressed genes (DEGs) analysis was performed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database and four clusters were determined by a consistent clustering analysis. Three DEGs closely related to overall survival(OS)were identified using Cox regression and LASSO analysis. Then the hypoxia-related signature was developed and validated in TCGA and International Cancer Genome Consortium (ICGC) database. The Gene Set Enrichment Analysis (GSEA) was performed to explore signaling pathways regulated by the signature. CIBERSORT was used for estimating the fractions of immune cell types.ResultsA total of 397 hypoxia-related DEGs in HCC were detected and three genes (PDSS1, CDCA8 and SLC7A11) among them were selected to construct a prognosis, recurrence and diagnosis model. Then patients were divided into high- and low-risk groups. Our hypoxia-related signature was significantly associated with worse prognosis and higher recurrence rate. The diagnostic model also accurately distinguished HCC from normal samples and nodules. Furthermore, the hypoxia-related signature could positively regulate immune response. Meanwhile, the high-risk group had higher fractions of macrophages, B memory cells and follicle-helper T cells, and exhibited higher expression of immunocheckpoints such as PD1and PDL1.ConclusionsAltogether, our study showed that hypoxia-related signature is a potential biomarker for diagnosis, prognosis and recurrence of HCC, and it provided an immunological perspective for developing personalized therapies.

16 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TBTang Bufu
Tang Bufu
XHXuanzhang Huang
Xuanzhang Huang
WHWeiliang Hou
Weiliang Hou
JWJifeng Wang
Jifeng Wang
LWLing Wang
Ling Wang
Cancer treatment is experiencing a fundamental transformation from conventional cytotoxic methods to precision-based immunotherapeutic strategies. Emerging forms of regulated cell death (RCD), including ferroptosis, autophagy, and immunogenic cell death (ICD), are intricately linked to the dynamic remodeling of the tumor immune microenvironment (TIME), presenting unprecedented opportunities for cancer treatment. An effective anti-cancer immune response requires precise orchestration of cellular and molecular mediators involved in the "cancer-immunity cycle" to prevent tumor progression and ultimately achieve eradication.Among the numerous emerging RCD modalities, ferroptosis research demonstrates particular vibrancy. Xie et al. demonstrated through bibliometric analysis an exponential growth in ferroptosis research between 2014 and 2024, with a remarkable annual growth rate of 64.99%. The research focus is progressively shifting from basic mechanistic studies to clinical translation, particularly showcasing vast potential in overcoming drug resistance (Xie et al. 2025). Echoing this trend, Ma et al. discovered that FXYD6 in ovarian cancer metastasis exerts tumor-suppressive effects by inducing ferroptosis and, utilizing machine learning approaches, developed a predictive model that provides novel targets and tools for precision therapy (Ma et al. 2025a). Autophagy, another significant RCD modality, exhibits a complex dual role in cancer progression. Jalali et al.'s comprehensive review highlights that autophagy suppresses carcinogenesis in early-stage tumors by clearing damaged organelles; however, in advanced tumors, it may provide metabolic support for tumor cells, thereby promoting invasion, metastasis, and drug resistance (Jalali et al. 2025). Consequently, autophagy presents a challenging therapeutic target, with the key to future research lying in its regulation within an appropriate "therapeutic window." Furthermore, the strong coupling between autophagy and immune responses offers crucial insights for optimizing cellular therapies such as CAR-T. In the realm of precision delivery, innovative materials science is opening new avenues for tumor immunotherapy. The injectable immunotherapeutic hydrogel developed by Zhang et al. enables sustained local activation of the STING pathway following surgical resection in breast cancer, significantly enhancing dendritic cell maturation and T cell immune responses (Zhang et al. 2025). In preclinical studies, this system achieved complete remission without recurrence for up to 120 days, demonstrating the powerful potential of localized immune delivery systems. Beyond host factors, the gut microbiome has been shown to significantly influence immunotherapy responses. Ding et al. revealed that butyrate, a metabolite of Fusobacterium nucleatum, alters colorectal cancer sensitivity to immunotherapy by activating the autophagy-lysosomal pathway and downregulating the DNA repair factor MLH1 (Ding et al. 2025). In animal studies, the combination of butyrate with PD-L1 inhibitors demonstrated enhanced efficacy, suggesting that modulating the microbiome-immune axis could expand the population benefiting from immunotherapy.Advances in multi-omics technologies are ushering in novel opportunities for precision cancer diagnosis and treatment. He et al. constructed a distant metastasis prediction model based on multi-omics data from lung cancer patient exosomes, identifying the sphingolipid metabolism pathway as a critical mediator of metastasis. The model, comprising 15 proteins, achieved an AUC of 0.95 in external validation, enabling early identification of high-risk patients. This achievement exemplifies the potential of multi-omics data in translational oncology. Metabolic pathway remodeling not only drives tumor growth but also profoundly impacts immune responses (He et al. 2025). Ma et al. employed single-cell sequencing to reveal that programmed cell death (PCD)-related genes drive the immunosuppressive effects of the CEBPB⁺ fibroblast subpopulation in triple-negative breast cancer (TNBC) and are closely associated with poor prognosis. Their constructed prognostic model was validated in clinical samples and murine experiments, providing new avenues for improving TNBC immunotherapy (Ma et al. 2025b). Simultaneously, Han and colleagues concentrated their research efforts on disulfidptosis mechanisms, they demonstrated that this mechanism can predict endometrial cancer patients' responses to immunotherapy and characterize immune environment features, this suggests that novel cell death modalities may serve as important reference criteria for individualized therapy approaches (Han et al. 2024). Within clear cell renal cell carcinoma (ccRCC), ferroptosis exhibits complex functional characteristics, on one hand this mechanism can enhance anti-tumor immune responses through inducing cellular death, on the other hand it may accelerate tumor progression processes by excessively damaging immune cells. The deep understanding of ferroptosis and metabolic interactions explored by Chen and colleagues holds promise for driving the development processes of combination therapy regimens for renal cell carcinoma (He et al. 2024).Additionally, Shan and colleagues focused their attention on mucosal melanoma (MM) field, summarizing the potential value of immune checkpoint inhibitors, adoptive cell transfer therapy (ACT), anti-angiogenic treatments, and combination strategies in improving therapeutic effectiveness and overcoming drug resistance. This comprehensive methodology brings new hope for highly aggressive malignancies with historically limited effective treatment options (Shan and Liu 2024). Yang and colleagues identified osteoporosis biomarkers associated with cellular death and mitochondrial function through multi-omics analysis and experimental validation methods. Their research revealed these molecules not only participate in disease progression...